Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Synthesis  





2 References  














Mesoridazine






Cymraeg
فارسی
Polski
Српски / srpski
Srpskohrvatski / српскохрватски
Suomi
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Mesoridazine
Clinical data
Trade namesSerentil
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa682306
Routes of
administration
Oral, intravenous
Drug classTypical antipsychotic
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
  • Pharmacokinetic data
    Protein binding4%
    MetabolismHepatic/renal
    Elimination half-life24 to 48 hours
    ExcretionBiliary and renal
    Identifiers
    • 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfinylphenothiazine

    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC21H26N2OS2
    Molar mass386.57 g·mol−1
    3D model (JSmol)
    Melting point130 °C (266 °F)
    Solubility in waterinsoluble mg/mL (20 °C)
    • O=S(c2cc1N(c3c(Sc1cc2)cccc3)CCC4N(C)CCCC4)C

    • InChI=1S/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3 checkY

    • Key:SLVMESMUVMCQIY-UHFFFAOYSA-N checkY

      (verify)

    Mesoridazine (Serentil) is a phenothiazine class drug that is used in the treatment of schizophrenia.[2] It is one of the active metabolites of thioridazine. The drug's name is derived from the methylsulfoxy and piperidine functional groups in its chemical structure.

    It has central antiadrenergic, antidopaminergic, antiserotonergic and weak muscarinic anticholinergic effects.

    Serious side effects include akathisia, tardive dyskinesia and the potentially fatal neuroleptic malignant syndrome.

    Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram.[3]

    It currently appears to be unavailable worldwide. [citation needed]

    Synthesis[edit]

    Thieme Synthesis:[4][5] Patent:[6]

    2-Methylthiophenothiazine [7643-08-5] (1) is treated with acetic anhydride] to give the protected amide, ie 10-acetyl-2-methylthiophenothiazine, CID:69367526. Oxidation of this by means of hydrogen peroxide and removal of the acetyl protecting group with potassium carbonate in methanol solution gives 2-methylsulfonylphenothiazine [23503-68-6] (3). Introduction of the sidechain by alkylation with 2-(2-chlorethyl)-1-methylpiperidine [50846-01-0] (6) in the presence of sodamide, afforded the desired mesoridazine (5).

    References[edit]

    1. ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  • ^ Gershon S, Sakalis G, Bowers PA (December 1981). "Mesoridazine -- a pharmacodynamic and pharmacokinetic profile". The Journal of Clinical Psychiatry. 42 (12): 463–9. PMID 7031039.
  • ^ American Society of Health-System Pharmacists (AHFS). "Mesoridazine". Medline Plus. U.S. National Library of Medicine.
  • ^ Bourquin, J.-P.; Schwarb, G.; Gamboni, G.; Fischer, R.; Ruesch, L.; Guldimann, S.; Theus, V.; Schenker, E.; Renz, J. (1958). "Synthesen auf dem Phenothiazin-Gebiet. 1. Mitteilung. Mercaptophenothiazin-Derivate". Helvetica Chimica Acta. 41 (4): 1061–1072. doi:10.1002/hlca.19580410419.
  • ^ Bourquin, J.-P.; Schwarb, G.; Gamboni, G.; Fischer, R.; Ruesch, L.; Guldimann, S.; Theus, V.; Schenker, E.; Renz, J. (1958). "Synthesen auf dem Phenothiazin-Gebiet. 2. Mitteilung. N-substituierte Mercaptophenothiazin-Derivate". Helvetica Chimica Acta. 41 (4): 1072–1108. doi:10.1002/hlca.19580410420.
  • ^ Schwarb Gustav, Renz Jany, Bourquin Jean-Pierre, U.S. patent 3,084,161 (1963 to Sandoz Ltd).
  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Mesoridazine&oldid=1228987876"

    Categories: 
    Muscarinic antagonists
    Phenothiazines
    Piperidines
    Sulfoxides
    Tertiary amines
    Typical antipsychotics
    Withdrawn drugs
    Nervous system drug stubs
    Hidden categories: 
    CS1 Brazilian Portuguese-language sources (pt-br)
    Articles needing additional references from April 2024
    All articles needing additional references
    Articles with short description
    Short description is different from Wikidata
    Drugs with non-standard legal status
    Drugboxes which contain changes to watched fields
    All articles with unsourced statements
    Articles with unsourced statements from June 2024
    All stub articles
     



    This page was last edited on 14 June 2024, at 07:04 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki